{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:15:25Z","timestamp":1761488125068},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T00:00:00Z","timestamp":1223337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1038\/sj.bjc.6604708","type":"journal-article","created":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T20:48:37Z","timestamp":1223412517000},"page":"1395-1401","source":"Crossref","is-referenced-by-count":14,"title":["Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer"],"prefix":"10.1038","volume":"99","author":[{"given":"T","family":"Conroy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Viret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J F","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Boige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ychou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J P","family":"Metges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Yataghene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Peiffert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,7]]},"reference":[{"key":"BF6604708_CR1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0959-8049(97)00088-9","volume":"33","author":"H Bleiberg","year":"1997","unstructured":"Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216\u20131220","journal-title":"Eur J Cancer"},{"key":"BF6604708_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejca.2006.07.021","volume":"43","author":"N Bossard","year":"2007","unstructured":"Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM, Guizard AV, Tretarre B, Launoy G, Colonna M, Danzon A, Molinie F, Troussard X, Bourdon-Raverdy N, Carli PM, Jaffr\u00e9 A, Bessaguet C, Sauleau E, Schvartz C, Arveux P, Maynadi\u00e9 M, Grosclaude P, Est\u00e8ve J, Faivre J (2007) Survival of cancer patients in France: a population-based study from the Association of the French Cancer Registries (FRANCIM). Eur J Cancer 43: 149\u2013160","journal-title":"Eur J Cancer"},{"key":"BF6604708_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2005.08.038","volume":"42","author":"AM Bouvier","year":"2006","unstructured":"Bouvier AM, Binquet C, Gagnaire A, Jouve JL, Faivre J, Bedenne L (2006) Management and prognosis of esophageal cancers: has progress been made? Eur J Cancer 42: 228\u2013233","journal-title":"Eur J Cancer"},{"key":"BF6604708_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson Jr JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SI, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer. Long term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 281: 1623\u20131627","journal-title":"JAMA"},{"issue":"18S part I","key":"BF6604708_CR5","doi-asserted-by":"crossref","first-page":"LBA4017","DOI":"10.1200\/jco.2006.24.18_suppl.lba4017","volume":"24","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Rao S, Starling N, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman JAR, NCRI Upper GI Study Group (2006) Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: the REAL 2 trial. J Clin Oncol 24: 18S (part I): LBA4017","journal-title":"J Clin Oncol"},{"key":"BF6604708_CR6","unstructured":"Declaration of Helsinki Laid down by the 18th World Medical Assembly (Helsinki, 1964) and amendments laid down by the 29th (Tokyo, 1975), the 35th (Venice, 1983), the 41st (Hong Kong, 1989) and the 48th (Somerset West, 1996) World Medical Assemblies"},{"key":"BF6604708_CR7","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938\u20132947","journal-title":"J Clin Oncol"},{"key":"BF6604708_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/bjc.1993.75","volume":"67","author":"MS Highley","year":"1993","unstructured":"Highley MS, Hill ME, Ziras N, Samandas N, Mason RC, Owen W, Dussek J, Barker S, Harper PG (1993) High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma. Br J Cancer 67: 407\u2013408","journal-title":"Br J Cancer"},{"key":"BF6604708_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/bjc.1991.358","volume":"64","author":"PW Johnson","year":"1991","unstructured":"Johnson PW, Thompson PI, Seymour MT, Deasy NP, Thurainsingham RC, Slevin ML, Wrigley PF (1991) A less toxic regimen of 5FU and high dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer 64: 603\u2013605","journal-title":"Br J Cancer"},{"key":"BF6604708_CR10","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1200\/JCO.2002.12.032","volume":"20","author":"NI Khushalani","year":"2002","unstructured":"Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L (2002) Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20: 2844\u20132850","journal-title":"J Clin Oncol"},{"key":"BF6604708_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/oxfordjournals.annonc.a057914","volume":"2","author":"C Louvet","year":"1991","unstructured":"Louvet C, de Gramont A, Demuynck B, Nordlinger B, Maisani JE, Lagadec B, Delfau S, Varette C, Gonzalez-Canali G (1991) High dose folinic acid, 5FU bolus and continuous infusion in poor prognosis patients with advanced measurable gastric cancer. Ann Oncol 2: 229\u2013230","journal-title":"Ann Oncol"},{"key":"BF6604708_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1200\/JCO.1986.4.5.685","volume":"4","author":"D Machover","year":"1986","unstructured":"Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vandenbulcke JM, Misset JL, Schwarzenberg L, Fourtillan JB (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5FU and high-dose folinic acid. J Clin Oncol 4: 685\u2013695","journal-title":"J Clin Oncol"},{"key":"BF6604708_CR13","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/annonc\/mdi249","volume":"16","author":"AM Mauer","year":"2005","unstructured":"Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, Vokes EE, for the University of Chicago Phase II Network (2005) Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 16: 1320\u20131325","journal-title":"Ann Oncol"},{"key":"BF6604708_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijrobp.2004.09.009","volume":"62","author":"J Maurel","year":"2005","unstructured":"Maurel J, Cervantes A, Conill C, Salazar R, Martin-Richard M, Pera M, Manzano H, Chirivella I, Gallego R, Marfa X (2005) Phase I trial of oxaliplatin in combination with cisplatin, protracted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. Int J Radiat Oncol Biol Phys 62: 91\u201396","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF6604708_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20: 1167\u20131174","journal-title":"J Clin Oncol"},{"key":"BF6604708_CR16","unstructured":"National Cancer Institute (of the United States of America, NCI). Common Terminology Criteria for Adverse Events (CTC-AE), version 2.0. Available at: http:\/\/ctep.info.nih.gov\/reporting\/ctc.html"},{"key":"BF6604708_CR17","unstructured":"Note for Guidance from the European Agency for the Evaluation of Medicines (EMEA) (2003) Committee for Proprietary Medicinal Products (CPMP) adopted guideline. Note for Guidance on Evaluation of Anticancer Medicinal Products in Man \u2013 CPMP\/EWP\/205\/95rev.2 \u2013 corr, London, 24 July"},{"key":"BF6604708_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/PPO.0b013e318046ee1a","volume":"13","author":"BM O'Connor","year":"2007","unstructured":"O'Connor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM (2007) Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J 13: 119\u2013124","journal-title":"Cancer J"},{"key":"BF6604708_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74\u2013108","journal-title":"CA Cancer J Clin"},{"key":"BF6604708_CR20","unstructured":"Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds) (2008) SEER Cancer Statistics Review, 1975\u20132005, National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975_2005\/ based on November 2007 SEER data submission, posted to the SEER web site, 2008.Accessed 18 April"},{"key":"BF6604708_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0959-8049(95)00524-2","volume":"32A","author":"E Roca","year":"1996","unstructured":"Roca E, Pennella E, Sardi M, Carraro S, Barugel M, Milano C, Fiorini A, Giglio R, Gonzalez G, Kneitschel R, Aman E, Jarentchuk A, Blajman C, Nadal J, Santarelli MT, Navigante A (1996) Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer. Eur J Cancer 32A: 429\u2013432","journal-title":"Eur J Cancer"},{"key":"BF6604708_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<1888::AID-CNCR7>3.0.CO;2-B","volume":"78","author":"J Rubin","year":"1996","unstructured":"Rubin J, Gallagher JG, Schroeder G, Schutt AJ, Dalton RJ, Kugler JW, Morton RF, Mailliard JA, Burch PA (1996) Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 78: 1888\u20131891","journal-title":"Cancer"},{"issue":"Suppl 5","key":"BF6604708_CR23","doi-asserted-by":"publisher","first-page":"v61","DOI":"10.1093\/annonc\/mdg754","volume":"14","author":"M Sant","year":"2003","unstructured":"Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, H\u00e9delin G, Matsuda T, M\u00f8ller H, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P, Lisi D (2003) EUROCARE-3: survival of cancer patients diagnosed 1990\u201394. Results and commentary. Ann Oncol 14 (Suppl 5): v61\u2013v118","journal-title":"Ann Oncol"},{"key":"BF6604708_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0959-8049(94)90250-X","volume":"30A","author":"M Stahl","year":"1994","unstructured":"Stahl M, Wilke H, Meyer HJ, Preusser P, Berns T, Fink U, Achterrath W, Knipp H, Harstrick A, Berger M, Schmoll HJ (1994) 5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. Eur J Cancer 30A: 325\u2013328","journal-title":"Eur J Cancer"},{"key":"BF6604708_CR25","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/sj.bjc.6603750","volume":"96","author":"E van Meerten","year":"2007","unstructured":"van Meerten E, Esken FALM, van Gameren EC, Doorn L, van der Gaast A (2007) First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer 96: 1348\u20131352","journal-title":"Br J Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6604708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604708","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6604708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:36:09Z","timestamp":1684413369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6604708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,7]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["BF6604708"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6604708","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,7]]}}}